NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free ZLAB Stock Alerts $18.08 -0.39 (-2.11%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$17.95▼$19.0050-Day Range$17.73▼$26.5652-Week Range$17.68▼$40.42Volume349,640 shsAverage Volume659,173 shsMarket Capitalization$1.79 billionP/E RatioN/ADividend YieldN/APrice Target$64.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Zai Lab alerts: Email Address Zai Lab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside255.2% Upside$64.22 Price TargetShort InterestHealthy4.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 12 Articles This WeekInsider TradingSelling Shares$728,132 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.09) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.58 out of 5 starsMedical Sector517th out of 947 stocksPharmaceutical Preparations Industry241st out of 435 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $64.22, Zai Lab has a forecasted upside of 255.2% from its current price of $18.08.Amount of Analyst CoverageZai Lab has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.11% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Zai Lab has recently decreased by 13.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 2.0 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Zai Lab this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $728,132.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions43.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($3.09) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 About Zai Lab Stock (NASDAQ:ZLAB)Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More ZLAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Stock News HeadlinesMarch 17, 2024 | finance.yahoo.comZLAB Apr 2024 12.500 putMarch 17, 2024 | finance.yahoo.comZLAB Apr 2024 25.000 callMarch 19, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 17, 2024 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Down to $19.55March 16, 2024 | finance.yahoo.comZLAB Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comZLAB Apr 2024 17.500 putMarch 16, 2024 | finance.yahoo.comZLAB Apr 2024 22.500 callMarch 16, 2024 | finance.yahoo.comZLAB Apr 2024 20.000 putMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zai Lab Amid Strong Sales Performance and Positive Development OutlookMarch 14, 2024 | seekingalpha.comStock Disconnect Triggers Investor Exodus From CStone PharmaMarch 13, 2024 | businesswire.comZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid TumorsMarch 6, 2024 | finance.yahoo.comZai Lab Announces Participation in March Investor ConferenceMarch 6, 2024 | businesswire.comZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)March 1, 2024 | seekingalpha.comZai Lab Limited (ZLAB) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zai Lab Amidst Strong Growth and Positive Future OutlookFebruary 29, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zai Lab on Strong Product Performance and Upbeat Revenue ProjectionsFebruary 28, 2024 | markets.businessinsider.comZai Lab’s Growth and Pipeline Prompts Buy Rating: Analyst David Li’s Financial Outlook and Price ObjectiveFebruary 27, 2024 | benzinga.comRecap: Zai Lab Q4 EarningsFebruary 27, 2024 | finance.yahoo.comZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate UpdatesFebruary 27, 2024 | finance.yahoo.comZai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial ResultsFebruary 27, 2024 | businesswire.comZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate UpdatesFebruary 21, 2024 | realmoney.thestreet.comZai Lab price target lowered by $6 at BofA, here's whyFebruary 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Globus Medical (GMED) and Zai Lab (ZLAB)February 19, 2024 | finance.yahoo.comZLAB Mar 2024 12.500 callFebruary 19, 2024 | finance.yahoo.comZLAB Mar 2024 20.000 putSee More Headlines Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/18/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,175Year FoundedN/APrice Target and Rating Average Stock Price Target$64.22 High Stock Price Target$73.34 Low Stock Price Target$47.50 Potential Upside/Downside+255.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-334,620,000.00 Net Margins-125.46% Pretax Margin-125.46% Return on Equity-37.07% Return on Assets-30.72% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.41 Sales & Book Value Annual Sales$266.72 million Price / Sales6.70 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book2.25Miscellaneous Outstanding Shares98,840,000Free Float93,670,000Market Cap$1.79 billion OptionableOptionable Beta1.13 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Ying Du Ph.D. (Age 58)Founder, Chairperson & CEO Comp: $1.67MMr. Joshua L. Smiley (Age 54)President & COO Comp: $647.11kDr. Rafael G. Amado M.D. (Age 60)President and Head of Global Oncology Research & Development Comp: $477kDr. Harald Reinhart M.D. (Age 72)President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases Comp: $923.33kDr. Yajing Chen Ph.D.Chief Financial OfficerDr. Peter Huang Ph.D.Chief Scientific OfficerMs. Christine ChiouSenior VP & Head of Investor RelationsMr. Frazor Titus Edmondson III (Age 58)J.D., Chief Legal Officer & Corporate Secretary Comp: $829kMs. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 59)Executive VP & Head of Clinical Operations More ExecutivesKey CompetitorsMaravai LifeSciencesNASDAQ:MRVICatalyst PharmaceuticalsNASDAQ:CPRXSchrödingerNASDAQ:SDGRArdelyxNASDAQ:ARDXSyndax PharmaceuticalsNASDAQ:SNDXView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 3,413,829 shares on 3/5/2024Ownership: 5.399%Price T Rowe Associates Inc. MDSold 12,139 shares on 2/16/2024Ownership: 2.736%GSA Capital Partners LLPBought 11,021 shares on 2/16/2024Ownership: 0.011%Price T Rowe Associates Inc. MDSold 12,139 shares on 2/15/2024Ownership: 2.736%Citadel Advisors LLCBought 4,300 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ZLAB Stock Analysis - Frequently Asked Questions Should I buy or sell Zai Lab stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks. What is Zai Lab's stock price target for 2024? 5 analysts have issued twelve-month price targets for Zai Lab's stock. Their ZLAB share price targets range from $47.50 to $73.34. On average, they anticipate the company's share price to reach $64.22 in the next year. This suggests a possible upside of 255.2% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts. How have ZLAB shares performed in 2024? Zai Lab's stock was trading at $27.33 at the beginning of the year. Since then, ZLAB stock has decreased by 33.8% and is now trading at $18.08. View the best growth stocks for 2024 here. When is Zai Lab's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ZLAB earnings forecast. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) released its earnings results on Tuesday, November, 9th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.24) by $0.23. The business earned $43.10 million during the quarter, compared to the consensus estimate of $42.43 million. Zai Lab had a negative trailing twelve-month return on equity of 37.07% and a negative net margin of 125.46%. What ETFs hold Zai Lab's stock? ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP) and Loncar China Biopharma ETF (CHNA).Invesco Golden Dragon China ETF (PGJ) and What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN). When did Zai Lab IPO? (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's stock is owned by many different institutional and retail investors. Top institutional investors include Wellington Management Group LLP (5.40%), Price T Rowe Associates Inc. MD (2.74%), Price T Rowe Associates Inc. MD (2.74%), Viking Global Investors LP (1.89%), Segantii Capital Management Ltd (1.71%) and Legal & General Group Plc (0.84%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Peter Wirth, Rafael Amado, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZLAB) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.